Navigation Links
Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
Date:10/23/2013

MILLBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee.

Dr. Fury is a Medical Oncologist in The Department of Medicine at Memorial Sloan-Kettering. Since 2006 Dr. Fury has been conducting clinical research focused on mTOR/eIF4E inhibitors for Human Papilloma related head and neck cancers. He will now be participating in a collaboration with Egenix in the development of a drug for HPV.

We at Egenix are delighted to have Dr. Fury aboard.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Egenix, Inc. Announces New Director, John Reid
2. Egenix, Inc. Announces New Director
3. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
4. ACTUS Appoints New Members to Its Management Team
5. Immune Design Appoints Stephen R. Brady Chief Business Officer
6. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
7. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
8. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
9. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
10. Senn Chemicals Appoints New Chief Executive Officer
11. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... CALIF. (PRWEB) , ... October 10, 2017 , ... San ... part of its corporate rebranding initiative announced today. The bold new look is ... reach, as the company moves into a significant growth period. , It will also ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):